Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 0.37 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.36 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446596 | 0.83 | OTC (0.46) | OTC | |
| SCHEMBL20178595 | 0.83 | OTC (0.46) | OTC | |
| SCHEMBL16446954 | 0.81 | NOS2 (0.44) | — | |
| SCHEMBL16446881 | 0.81 | NOS3 (0.44) | — | |
| SCHEMBL17852276 | 0.81 | NOS2 (0.44) | — | |
| SCHEMBL28260909 | 0.81 | NOS2 (0.44) | — | |
| SCHEMBL22180584 | 0.80 | OTC (0.36) | GFPT1OTC | |
| SCHEMBL15473014 | 0.79 | OTC (0.40) | OTC | |
| SCHEMBL24610028 | 0.76 | OTC (0.44) | OTC | |
| SCHEMBL15469218 | 0.76 | GFPT1 (0.36) | GFPT1OTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11548852-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4074728-A1 | MODIFIED PEPTIDES COMPRISING AN AZIDO GROUP | Sutro Biopharma, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20160251336-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| WO-2015054658-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015006555-A2 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140066598-A1 | Modified Amino Acids | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014036492-A1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140066598-A1 | Modified Amino Acids | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | FCGR2A, FCGR3B, FCGR1A | CASR 4059/4885GFPT1 373/4885OTC 3494/4885 |
| US-11548852-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | CASR 3959/4885GFPT1 401/4885OTC 1469/4885 |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | CASR 3449/4885GFPT1 4316/4885OTC 3340/4885 |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | CD74, CD63, CD99 | CASR 3584/4885GFPT1 4241/4885OTC 3319/4885 |
| US-20140066598-A1 | Modified Amino Acids | PTMS, DNPEP, ANPEP | CASR 3959/4885GFPT1 401/4885OTC 1469/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | CASR 3747/4885GFPT1 3002/4885OTC 4749/4885 |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | CASR 3959/4885GFPT1 401/4885OTC 1469/4885 |
| US-20160251336-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | DNPEP, SLC1A5, AADAT | CASR 4086/4885GFPT1 359/4885OTC 1207/4885 |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | DNPEP, LNPEP, ANPEP | CASR 3411/4885GFPT1 559/4885OTC 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.